Back to Newsroom

GEN: Small Molecules, Big Possibilities

Selective, targeted small molecule drug candidates are moving through the clinical development pipeline in a range of disease indications.

While the current generation of small molecule drugs in clinical trials share some key advantages with small molecule therapeutics already on the market, such as oral bioavailability and less complex synthetic processes compared to biopharmaceuticals in general, many of these new compounds are first-in-class drugs and have novel targets and mechanisms of actions.

Click here to read more